After reviewing the health hazards posed by different medications produced in the country, a committee of the drug administration has recommended banning the manufacture and the import of raw materials for six generic drugs of local pharmaceutical companies
Two of the generic drugs – Pioglitazone and Rosiglitazone – are used for the treatment of diabetes, while the rest – Flupenthixol-Melitracen, Gatifloxacin (except eye drops), Tegaserod and Sibutramine – are used for treating patients with psychotic diseases, bacterial infections, irritable bowel syndrome and obesity respectively.
Selim Barami, director of the Directorate General of Drug Administration (DGDA), said they would now submit the report before the national adverse drug reaction advisory committee, which is headed by Health Secretary MM Niazuddin. The final decision on banning or cancelling the generic drugs will come from the central committee, he added.
The Adverse Drug Reaction Advisory Committee (ADRAC) reportedly passed the resolution on March 30, following a separate meeting earlier on March 12, which was presided over by Major General Jahangir Hossain Mollik, the directorate’s DG and head of the 16-member ADRAC.
The senior doctors and health sector officials who were present at the meeting unanimously agreed that all of the six drugs had excessive adverse reaction, adding that safety and efficacy were the foremost preconditions to manufacturing and marketing of a drug.
Nayar Sultana, member secretary of the ADRAC, told the meeting that many other countries had already banned the six generic drugs because of their excessive adverse reaction.
Mir Misbahuddin, professor of pharmacology at the BSMMU, echoed Nayar and said Bangladesh should follow similar measures.
Md Faizul Alam Chowdhury, professor of medicine at the DMCH, said almost no one prescribed Tegaserod and Sibutramine anymore, as most of the doctors knew about the adverse reaction. However, some doctors continue to prescribe Pioglitazone, Rosiglitazone and Gatifloxacin.
Faizul said it was common among doctors to prescribe Flupenthixol-Melitracen, adding that it should be banned in Bangladesh considering risk-benefit ratio.
Naser Shahriar Zahedi, president of Bangladesh Pharmaceuticals Society, emphasised on the need to ensure the safety and efficacy of the drugs. Calling for bans on the six generic drugs, Zahedi however recommended that the pharmaceutical companies be allowed to finish the raw materials they already had in stock.
AKM Shamshuzzaman, chief scientific officer of the Institute of Epidemiology, Disease Control and Research (IEDCR), said abnormal heart rhythms caused by Flupenthixol-Melitracen prompted India, the UK, the USA, Ireland, Canada, Japan and Australia to ban the drug.
The drugs
It is learnt that Pioglitazone is used for treating type 2 diabetes in certain patients. It works by lowering blood sugar by making the cells of the body more sensitive to the action of insulin.
Rosiglitazone is an oral drug also used in treating type 2 diabetes patients, as the drug reduces the amount of sugar (glucose) in the blood.
Flupentixol is an antipsychotic drug used to treat schizophrenia and other psychotic diseases. It is also used in many cases on low doses as an antidepressant.
Gatifloxacin is used to treat a variety of bacterial infections. It works by stopping the growth of bacteria.
Tegaserod is used to treat irritable bowel syndrome in women who have constipation as a major symptom. Tegaserod relieves constipation by shortening the time stool remains in the bowel, reducing stomach pain and bloating.
Sibutramine is used for treating obesity. It regulates chemicals in the brain that reduce hunger or craving for food.



